Quarterly report [Sections 13 or 15(d)]

Note 7 - Stockholders' Equity (Details Textual)

v3.26.1
Note 7 - Stockholders' Equity (Details Textual)
 6 Months Ended 41 Months Ended
Jun. 24, 2024
shares
May 10, 2024
$ / shares
Feb. 03, 2023
USD ($)
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Dec. 31, 2025
$ / shares
shares
Jan. 30, 2023
shares
Sep. 22, 2022
Dec. 31, 2021
shares
Sep. 13, 2019
$ / shares
Sep. 13, 2016
shares
Preferred Stock, Shares Authorized (in shares)       2,000,000   2,000,000 2,000,000         2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0001   $ 0.0001 $ 0.0001          
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.0001   $ 0.0001   $ 0.0001 $ 0.0001          
Proceeds from Issuance of Common Stock | $       $ 0 $ 2,094,000              
Invagen Pharmaceuticals Inc [Member]                        
Contingent Fee, Percentage of Proceeds of Future Financings     7.50%                  
Contingent Fee, Maximum Allowable Amount | $     $ 4,000,000                  
Payment of Contingent Fee | $       0 $ 200,000 $ 1,400,000            
Restricted Stock Units (RSUs) [Member]                        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $       $ 19,000   $ 19,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       3 months 18 days                
Deferred Restricted Stock Units [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)       235,000   235,000            
Share-Based Payment Arrangement, Option [Member]                        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $       $ 50,000   $ 50,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       4 months 24 days                
Two Thousand Fifteen Incentive Plan [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 5,070,223                 3,556    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       4,575,906   4,575,906            
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) 10 years                      
Two Thousand Fifteen Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 5,000,000                      
Two Thousand Fifteen Incentive Plan [Member] | Maximum [Member] | Share-Based Payment Arrangement, Nonemployee [Member]                        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)               70,223        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 500,000                      
ATM Agreement [Member]                        
Stock Issued During Period, Shares, New Issues (in shares)         938,990              
Proceeds from Issuance of Common Stock | $         $ 2,100,000              
Commission Fee, Percent Fee   3.00%                    
Preferred Class A [Member]                        
Preferred Stock, Shares Authorized (in shares)                       250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares                     $ 0.0001  
Preferred Stock, Convertible, Conversion Ratio                 1,125